Generalized Myasthenia Gravis (gMG) is a chronic neuromuscular disorder that significantly impacts patients’ health-related quality of life (HRQoL). Despite advancements in disease management, many individuals with gMG continue to experience debilitating symptoms, persistent physical and mental fatigue, and challenges in daily activities. Current treatment options, including corticosteroids, intravenous immunoglobulins, and plasma exchange, are often limited by toxicity profiles, delayed onset of action, and inconsistent efficacy. Novel therapies such as FcRn antagonists and C5 complement inhibitors offer promising alternatives with targeted mechanisms of action and improved safety profiles. This educational initiative aims to enhance clinician competence in evaluating the efficacy and safety of FcRn and C5 complement inhibitors and integrating formal HRQoL assessments, such as the MG-QOL15r, into gMG management. By bridging these gaps, healthcare providers can optimize treatment strategies, improve patient outcomes, and address the unmet needs of those living with gMG.
- Provider:CME Outfitters, LLC
- Activity Link: https://www.cmeoutfitters.com
- Start Date: 2025-02-28 06:00:00
- End Date: 2025-02-28 06:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.5 hours
AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours
Pharmacy: 0.5 hours - MOC Credit Details: ABIM - 0.5 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: argenx - Amount: 0 - Is Kind Support: False Source: UCB - Amount: 0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Internal Medicine